gfp vap b  (Addgene inc)

Journal: bioRxiv

Article Title: Selective MOSPD2-STARD3 interaction at ER contact sites governs late endosome/lysosome dynamics and cholesterol homeostasis

doi: 10.64898/2026.03.30.714413

Figure Lengend Snippet: A-B: Immunoprecipitation (anti-Flag) experiments between Flag-STARD3 and GFP-VAP-A, GFP-VAP-B, GFP-MOSPD2, GFP-MOSPD2 RD/LD, and GFP-VAP-A KD/MD (B) in HeLa cells. Approximatively 5 µg of total protein extract was analyzed by Western blot using anti-GFP, anti-STARD3, and anti-GAPDH antibodies. Immunoprecipitated proteins were analyzed using anti-GFP and anti-STARD3 antibodies. C: Immunoprecipitation between endogenous STARD3 and VAP-A, VAP-B and MOSPD2 in HCC1954 cells. Immunoprecipitation was performed using control IgG or anti-STARD3 antibodies in triplicate. Total protein extracts and immunoprecipitated proteins were analyzed by Western blot using anti-MOSPD2, anti-VAP-A, anti-VAP-B, anti-STARD3, and anti-GAPDH antibodies. *: aspecific. D: Principle of the native Holdup assay. Total protein extracts (a) are incubated with streptavidin resin saturated with a biotinylated MSP domain or control resin (b). After reaching equilibrium, unbound proteins are filtered out and quantified by Western blot. Binding intensity = 1 – (C Unbound / C total ). E: Coomassie blue staining of recombinant proteins used for native Holdup experiments: MBP alone or fused to the MSP domains of VAP-A, VAP-B or MOSPD2 (WT and RD/LD mutant), tagged with a 6 His for purification and biotinylated thanks to an AviTag. A total of 25 pmol of each protein was loaded. F: Native Holdup experiments quantifying the interaction between the recombinant MSP domains of VAP-A, VAP-B, MOSPD2, and MOSPD2 RD/LD and endogenous STARD3. Left: western blot analysis of the unbound prey protein (STARD3) in HCC1954 protein extracts after incubation with increasing amounts of the recombinant MSP domains. Right: Binding intensity between the MSP domains and the prey protein (STARD3). Binding curves were fitted using a Hill equation (mean ± SEM from 2 technical replicates), and apparent affinities ( K app ) and maximal binding intensities ( B max ) were calculated (± SD). G: FRAP experiment in HeLa cells co-expressing mCherry-STARD3 and either GFP-VAP-A, GFP-VAP-B, or GFP-MOSPD2. a: images showing STARD3-positive LE/Lys in close apposition to ER-localized GFP-MOSPD2 (top), GFP-VAP-A (middle), or GFP-VAP-B (bottom). Left: colocalization of mCherry-STARD3 (magenta) and GFP (green) pre-bleach. GFP signal (gray) displayed sequentially from left to right: pre-bleach, immediately post-bleach, 3 seconds post-bleach, and 20 s post-bleach. b: Quantification of relative GFP-signal intensity in the bleached ROI during the 2 seconds before bleaching, and the 21 seconds following bleaching in cells expressing GFP-VAP-A (blue curve), GFP-VAP-B (green curve), and GFP-MOSPD2 (red curve). The gray curve represents the GFP signal in the absence of bleaching. Mean values and standard deviations (black bars) are shown. The calculated half-times of recovery (mean t½ ± SD) are indicated.

Article Snippet: The pQCXIP MOSPD2 (WT; RD/LD; ΔCRAL-TRIO; ΔMSP), pQCXIP GFP-MOSPD2 (WT: Addgene #186467; RD/LD #186468), pQCXIP mScarlet-MOSPD2 (WT: Addgene #186472; RD/LD Addgene #186476; W201E: Addgene plasmid #186477; ΔMSP; ΔCRAL-TRIO mutants), GFP-VAP-A (WT: Addgene #104447; KD/MD Addgene #104449), GFP-VAP-B (Addgene plasmid #104448), EGFP-ER[TM(SAC1)] (Addgene plasmid #186475), pQCXIP mScarlet-ER [TM(SAC1)] (Addgene plasmid # 186572), Flag-STARD3, GFP-VAP-A (WT and KD/MD mutant), and GFP-VAP-B, expression vectors were previously described ( , ; ; ; ).

Techniques: Immunoprecipitation, Western Blot, Control, Incubation, Binding Assay, Staining, Recombinant, Mutagenesis, Purification, Expressing

Journal: bioRxiv

Article Title: Selective MOSPD2-STARD3 interaction at ER contact sites governs late endosome/lysosome dynamics and cholesterol homeostasis

doi: 10.64898/2026.03.30.714413

Figure Lengend Snippet: A-B: Immunoprecipitation (anti-Flag) experiments between Flag-STARD3 and GFP-VAP-A, GFP-VAP-B, GFP-MOSPD2, GFP-MOSPD2 RD/LD, and GFP-VAP-A KD/MD (B) in HeLa cells. Approximatively 5 µg of total protein extract was analyzed by Western blot using anti-GFP, anti-STARD3, and anti-GAPDH antibodies. Immunoprecipitated proteins were analyzed using anti-GFP and anti-STARD3 antibodies. C: Immunoprecipitation between endogenous STARD3 and VAP-A, VAP-B and MOSPD2 in HCC1954 cells. Immunoprecipitation was performed using control IgG or anti-STARD3 antibodies in triplicate. Total protein extracts and immunoprecipitated proteins were analyzed by Western blot using anti-MOSPD2, anti-VAP-A, anti-VAP-B, anti-STARD3, and anti-GAPDH antibodies. *: aspecific. D: Principle of the native Holdup assay. Total protein extracts (a) are incubated with streptavidin resin saturated with a biotinylated MSP domain or control resin (b). After reaching equilibrium, unbound proteins are filtered out and quantified by Western blot. Binding intensity = 1 – (C Unbound / C total ). E: Coomassie blue staining of recombinant proteins used for native Holdup experiments: MBP alone or fused to the MSP domains of VAP-A, VAP-B or MOSPD2 (WT and RD/LD mutant), tagged with a 6 His for purification and biotinylated thanks to an AviTag. A total of 25 pmol of each protein was loaded. F: Native Holdup experiments quantifying the interaction between the recombinant MSP domains of VAP-A, VAP-B, MOSPD2, and MOSPD2 RD/LD and endogenous STARD3. Left: western blot analysis of the unbound prey protein (STARD3) in HCC1954 protein extracts after incubation with increasing amounts of the recombinant MSP domains. Right: Binding intensity between the MSP domains and the prey protein (STARD3). Binding curves were fitted using a Hill equation (mean ± SEM from 2 technical replicates), and apparent affinities ( K app ) and maximal binding intensities ( B max ) were calculated (± SD). G: FRAP experiment in HeLa cells co-expressing mCherry-STARD3 and either GFP-VAP-A, GFP-VAP-B, or GFP-MOSPD2. a: images showing STARD3-positive LE/Lys in close apposition to ER-localized GFP-MOSPD2 (top), GFP-VAP-A (middle), or GFP-VAP-B (bottom). Left: colocalization of mCherry-STARD3 (magenta) and GFP (green) pre-bleach. GFP signal (gray) displayed sequentially from left to right: pre-bleach, immediately post-bleach, 3 seconds post-bleach, and 20 s post-bleach. b: Quantification of relative GFP-signal intensity in the bleached ROI during the 2 seconds before bleaching, and the 21 seconds following bleaching in cells expressing GFP-VAP-A (blue curve), GFP-VAP-B (green curve), and GFP-MOSPD2 (red curve). The gray curve represents the GFP signal in the absence of bleaching. Mean values and standard deviations (black bars) are shown. The calculated half-times of recovery (mean t½ ± SD) are indicated.

Article Snippet: The pQCXIP MOSPD2 (WT; RD/LD; ΔCRAL-TRIO; ΔMSP), pQCXIP GFP-MOSPD2 (WT: Addgene #186467; RD/LD #186468), pQCXIP mScarlet-MOSPD2 (WT: Addgene #186472; RD/LD Addgene #186476; W201E: Addgene plasmid #186477; ΔMSP; ΔCRAL-TRIO mutants), GFP-VAP-A (WT: Addgene #104447; KD/MD Addgene #104449), GFP-VAP-B (Addgene plasmid #104448), EGFP-ER[TM(SAC1)] (Addgene plasmid #186475), pQCXIP mScarlet-ER [TM(SAC1)] (Addgene plasmid # 186572), Flag-STARD3, GFP-VAP-A (WT and KD/MD mutant), and GFP-VAP-B, expression vectors were previously described ( , ; ; ; ).

Techniques: Immunoprecipitation, Western Blot, Control, Incubation, Binding Assay, Staining, Recombinant, Mutagenesis, Purification, Expressing

Journal: bioRxiv

Article Title: Selective MOSPD2-STARD3 interaction at ER contact sites governs late endosome/lysosome dynamics and cholesterol homeostasis

doi: 10.64898/2026.03.30.714413

Figure Lengend Snippet: A-F: Confocal images of WT HeLa cells (A) and MOSPD2-deficient HeLa cells (B-F), either untransfected (A-B) or transfected with expression vectors encoding WT STARD3 (C), the STARD3 SD/PA mutant (D), the STARD3 S209A mutant (E), or GFP-VAP-A (F). LE/Lys were labeled with anti-LAMP1 antibodies (magenta), and STARD3 was detected using anti-STARD3 antibodies. G-H: Quantification of LE/Lys numbers (G) and sizes (H) under the conditions shown in panels A-F. Data are displayed as Superplots showing the mean per cell (small dots) and per independent experiment (large dots). Independent experiments (n = 3-4) are color-coded. Means and error bars (SD) are shown as black bars. Data were collected from 108 (WT), 95 (KO MOSPD2 NT), 86 (KO MOSPD2 + STARD3 WT), 84 (KO MOSPD2 + STARD3 SD/PA), 86 (KO MOSPD2 + STARD3 S209A), and 48 (KO MOSPD2 + VAP-A) cells. One-way ANOVA with Tukey’s multiple comparisons test (ns, not significant; ****, P < 0.0001; n = 3-4 independent experiments).

Article Snippet: The pQCXIP MOSPD2 (WT; RD/LD; ΔCRAL-TRIO; ΔMSP), pQCXIP GFP-MOSPD2 (WT: Addgene #186467; RD/LD #186468), pQCXIP mScarlet-MOSPD2 (WT: Addgene #186472; RD/LD Addgene #186476; W201E: Addgene plasmid #186477; ΔMSP; ΔCRAL-TRIO mutants), GFP-VAP-A (WT: Addgene #104447; KD/MD Addgene #104449), GFP-VAP-B (Addgene plasmid #104448), EGFP-ER[TM(SAC1)] (Addgene plasmid #186475), pQCXIP mScarlet-ER [TM(SAC1)] (Addgene plasmid # 186572), Flag-STARD3, GFP-VAP-A (WT and KD/MD mutant), and GFP-VAP-B, expression vectors were previously described ( , ; ; ; ).

Techniques: Transfection, Expressing, Mutagenesis, Labeling